Long-term Safety & Efficacy Study of DX-2930 (SHP643) to Prevent Acute

See also
Status	Clinical Trial	Phase
Completed	`NCT02865720` - Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)	Phase 3
Completed	`NCT04861090` - A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
Recruiting	`NCT05489640` - A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
Completed	`NCT02584959` - Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema	Phase 3
Completed	`NCT01826916` - EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema	Phase 2
Completed	`NCT04057131` - FIRAZYR General Drug Use-Results Survey (Japan)
Recruiting	`NCT05819775` - CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema	Phase 3
Recruiting	`NCT05397431` - A Survey of Lanadelumab in Participants With Hereditary Angioedema
Completed	`NCT02093923` - A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants	Phase 1
Completed	`NCT01541423` - A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Completed	`NCT03845400` - A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
Completed	`NCT02586805` - Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE	Phase 3
Completed	`NCT02052141` - Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema	Phase 3
Completed	`NCT03888755` - A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants	Phase 3
Recruiting	`NCT05147181` - A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Recruiting	`NCT05469789` - A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
Completed	`NCT05460325` - A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)	Phase 3
Completed	`NCT01095510` - CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12	Phase 2
Recruiting	`NCT05578417` - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
Withdrawn	`NCT01253382` - Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema	Phase 2/Phase 3

NCT number	NCT02741596
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 3
Start date	May 26, 2016
Completion date	October 31, 2019

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms